side effects of glp-1 receptor agonists liraglutide (GLP-1 agonist) – Efficacy and Adverse The expanding role of GLP-1

Prescription trends reflect increasing clinician and patient acceptance, partly driven by robust clinical trial data and heightened public awareness of obesity as a chronic disease

Gershon MD, Tack J

Sam Fazeli, director of research at Bloomberg Intelligence, said in a best-case scenario that the drug could only be launched in 2028, at which stage multiple competitors might be available. Outpaced by rivals Danuglipron was designed as a needle-free alternative to popular weight-loss shots from Novo Nordisk A/S and Eli Lilly & Co

Ro offers a variety of popular brands and compounded GLP-1s, available in vials and pens

So far, several unimolecular dual and triple agonists are in clinical evaluation and as of today, the improved metabolic efficacy does not seem to be compromised by reduced safety [25].

Obesity is no longer regarded as simply a failure of willpower but now a chronic illness with a biological cause (Couzin-Frankel Dec 2023)